



Jeffrey T. L. Smith, M.D., Joins Alder Biopharmaceuticals Management Team

Seattle, Washington, April 17, 2004—Alder Biopharmaceuticals Inc., an early stage antibody therapeutics company, today announced the addition of Jeffrey T. Smith, M.D., to the company's management team. "We are extremely gratified to bring him on as part of our management team," said Dr. Randall Schatzman, CEO and an Alder founder. "His knowledge of antibody therapeutics combined with his extensive clinical development expertise and familiarity with FDA approval processes make him a valuable part of this company's strategic focus moving forward."

Dr. Smith brings a long list of accomplishments to the Alder management team. Prior to joining Alder, he was Senior Director of Medical Research for Celltech R&D Inc., where he was responsible for planning and managing the CDP870 anti-TNF clinical trials for Rheumatoid Arthritis as well as several other key autoimmune clinical development programs. Prior to Celltech, he was Head of Clinical Pharmacology at Hoechst Marion Roussel Ltd, Senior Clinical Physician at The Proctor and Gamble Company, and Senior Research Physician in the Clinical Pharmacology Department at Glaxo Research and Development Ltd. He has been responsible for the early development of numerous important drugs including Zantac®, Lotronex®, Arava®, and the later stage development of CDP870, CDP484 and Metadate CD®. He remains active in the Rheumatology community and is a research member of the American College of Rheumatology. He also serves on the planning board of the Innovative Therapies in Autoimmune Diseases Meeting. Dr. Smith received his medical degree from Westminster Medical School in London and has post-graduate training in Gastroenterology at the Royal Free Hospital in London.

Alder's proprietary technologies accelerate the discovery and development of antibody therapeutics that will address significant unmet medical needs. The company's therapeutic focus is centered in autoimmune and inflammatory diseases with extensions into certain forms of cancer. Alder's unique contribution to the field of antibody therapeutics involves a platform of proprietary antibody technologies that industrializes the approach to developing, selecting and manufacturing antibody therapeutics. Alder's technologies dramatically accelerate progress to the clinic while at the same time providing an inexpensive and rapid route through product manufacturing.

For more information or to setup a non-disclosure agreement to learn about Alder's proprietary technologies in more detail, please contact Mark Litton, Chief Business Officer, at (425) 527-2701 or Litton@alderbio.com.

About Alder

Founded in January 2004, Alder Biopharmaceuticals uniquely identifies, develops, and manufactures novel antibody therapeutics to alleviate human suffering in the autoimmune and inflammatory disease areas. Alder's management team combines decades of industry experience with a proven track record for identifying and developing novel antibody therapeutics. Today the company is actively engaged in developing its own proprietary therapeutics and enabling partners through out-licensing of its technologies. For more information, please visit www.alderbio.com.

Media and Industry Inquiries:

Mark Litton, Ph.D.

Chief Business Officer, Alder Biopharmaceuticals Inc.

(425) 205-2920

litton@alderbio.com

Investor Relations:

Randall Schatzman, Ph.D.

CEO, Alder Biopharmaceuticals Inc.

(425) 205-2910

schatzman@alderbio.com

© 2004 Alder Biopharmaceuticals, Inc. Data subject to change.